

**Program for the 2005 Kern Aspen Lipid Conference
August 20-23, 2005**

***HDL Metabolism and Nuclear Receptors:
A New Frontier for the Treatment of Atherosclerosis***

Co-Chairs: Roger Newton, PhD and Ira Tabas, MD, PhD

Session I:

***HDL Metabolism, Structure and Function*
Saturday, August 20, 2005 – 1:00 pm - 5:00 pm
Phil Barter, Moderator**

Kerry-Anne Rye, PhD, “HDL Size and Structure - Relationship to Function and Metabolism,” Heart Research Institute, Sidney, Australia

Michael C. Phillips, Ph.D., “Lipid-Protein Interactions – Importance in Receptor Recognition,” MCP Hahnemann University, Philadelphia, Pennsylvania

Mary Sorci-Thomas, PhD, “Mutations of Apo A-I and Their Involvement in Disruption of Protein Conformations Altering Apo A-I Secretion,” Wake Forest University, Winston-Salem, North Carolina

Stanley L. Hazen, MD, PhD, “Functional Impairment of Apo A-I via Selective Oxidation by Myeloperoxidase,” Center for Cardiovascular Diagnostics, Cleveland Clinic, Cleveland, Ohio

Session II:

***Intracellular Lipid Trafficking and Signal Transduction*
Sunday, August 21, 2005 - 8:30 am- 12:30 pm
Peter Edwards, Moderator**

David Silver, PhD, “SRB1-Interacting Proteins in HDL Metabolism,” Columbia University, New York, New York

Phil Shaul, MD, “The Role of HDL in Nitric Oxide Mediated Mechanisms,” University of Texas Southwestern Medical Center, Dallas, Texas

Fred Maxfield, PhD, “Intracellular Trafficking of HDL-derived Cholesterol,” Weill Medical College, Cornell University, New York, New York

Alan Tall, MD, “ABCG1/G4: Key Mediators of HDL-Mediated Cholesterol Efflux,” Columbia University, New York, New York

**Program for the 2005 Kern Aspen Lipid Conference
August 20-23, 2005**

Session III:

**Protective Effects of HDL and Nuclear Receptor Activation on
Atherosclerosis**

Monday, August 22, 2005, 8:30 am - 12:30 pm

Ron Evans, Moderator

Peter Tontonoz, MD, PhD, “Mechanisms of LXR-Mediated Atheroprotection,”
University of California Los Angeles, California

Joyce Repa, PhD, “LXRs and Reverse Cholesterol Transport, Looking Beyond the
Macrophage,” The University of Texas Southwestern Medical Center, Dallas, Texas

Chris Glass, MD, PhD, “Transcriptional Regulation of Macrophage Activation and
Inflammation,” University of California San Diego at La Jolla, California

KERN LECTURE

Ronald Evans, PhD, “Importance of PPAR Receptor Subtypes in the Regulation of Lipid
Metabolism,” The Salk Institute, La Jolla, California

Session IV:

Genetics of HDL Variation and Therapeutic Applications of HDL

Tuesday, August 23, 2005, 8:00 am- 12:00 pm

Bryan Brewer, Moderator

Helen Hobbs, MD, “Genetics of HDL Variation and its Impact on CAD Risk,”
The University of Texas Southwestern Medical Center, Dallas, Texas

Prediman K. Shah, MD, “Protective Effects of HDL Infusions for the Treatment of
Atherosclerosis,” Cedars-Sinai Medical Center, Los Angeles, California

John J.P. Kastelein, MD, PhD, “Clinical Benefit of HDL Therapy in Patients With
Atherosclerosis and Endothelial Dysfunction,” University of Amsterdam, The Netherlands

Mark J. Bamberger, PhD, “Torcetrapib-Lipitor Combination for Treatment of Patients With
Atherosclerosis- Effects on Cholesterol Metabolism,” Pfizer Global R & D, Groton, Connecticut